#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Ori Warshavsky Email
Chief Operating Officer - US Operations . PolyPid
How to contact Ori Warshavsky
Join and see Ori's contact info for free!Phone
Current Roles
Employees:
67Revenue:
$6.7MAbout
PolyPid®, a specialty pharmaceutical company, develops and manufactures products based on its PLEX? technology. So far, 70 patients have been treated in clinical trials with PolyPid?s anti-infection products demonstrating safety and efficacy. PolyPid is in the process of submitting its lead product for Phase-III trial in the US and EU. PLEX? is able to optimize drugs'? therapeutic performance and clinical outcomes. PLEX?-based protected drug reservoir is implanted directly into the body?s target area thus enabling prolonged delivery of drugs, over periods ranging from days to several months. PolyPid?s pipeline focuses on 3 products: D-PLEX? - intended for prevention and treatment of surgical infections caused by bacteria. Its effectiveness is currently being tested in patients undergoing open-heart surgery, with a view to preventing infections that may occur following surgery. The product is currently undergoing clinical studies at several medical centers. BonyPid®-1000 - designed to encourage bone healing and prevent bacterial infections in severe open fractures, usually caused by high-energy injuries. Tested in human studies, this product was shown to be safe and effective. Clinical trials demonstrated a decrease in amputations from 7% to 0%, 50% reduction in healing time and a drastically reduced infection rate from 25.5% to 0%. The product is undergoing a pivotal clinical trial prior to obtaining a European CE mark. BonyPid®-500 is designed to treat chronic infections in dental implants. The product is in a clinical trial in cooperation with Dentsply Sirona. Over the years PLEX? has shown a remarkable ability to encapsulate a wide variety of drugs, and has increased efficacy of two major US biotechnology companies? protein-based drugs. PolyPid is currently in the initial stages of establishing collaborative agreements with leading pharmaceutical companies. PolyPid?s technology was invented by Dr. Noam Emanuel, PolyPid?s founder and CTO.PolyPid Address
47 Maple St.null, null